Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
4
67%
Ph phase_2
2
33%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(2)
Terminated(2)
Other(2)

Detailed Status

unknown2
Completed2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

unknown233%
completed233%
terminated117%
withdrawn117%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_1

Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia

NCT03760523
completedphase_2

Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)

NCT04896073
unknownphase_1

Minnelide™ Capsules Alone and in Combination With Paclitaxel in Advanced Gastric Cancer

NCT05566834
completedphase_2

A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer

NCT03117920
unknownphase_1

Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas

NCT05557851
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03760523Phase 1

Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia

Terminated
NCT04896073Phase 2

Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)

Completed
NCT05566834Phase 1

Minnelide™ Capsules Alone and in Combination With Paclitaxel in Advanced Gastric Cancer

Unknown
NCT03117920Phase 2

A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer

Completed
NCT05557851Phase 1

Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas

Unknown
NCT03347994Phase 1

Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6